• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Fractyl Health

Fractyl Health

Transformative Metabolic Therapies

  • Investors
  • Clinical Studies
  • Careers
  • Our Focus
    • Obesity
    • Type 2 Diabetes
  • Our Platforms
    • Revita
    • Rejuva
  • Our Science
    • Clinical Studies
    • Presentations & Publications
  • Our Company
    • Culture
    • Our Team
    • Careers
  • Our News
    • Media Kit
Home/Revita

Duodenal Mucosal Resurfacing Stabilizes Weight Loss and Glycemic Control After Glucagon-Like Peptide-1 Receptor Agonist Withdrawal: REVEAL-1 – A Prospective Multicenter Open-Label Study

Revita

May 6, 2026 by

May 6, 2026 by

November 4, 2025 by

March 21, 2025 by

November 3, 2024 by

October 5, 2024 by

May 13, 2024 by

April 26, 2024 by

April 26, 2024 by

  • Page 1
  • Page 2
  • Page 3
  • Interim pages omitted …
  • Page 8
  • Go to Next Page »

Footer

LinkedIn X, formally Twitter Facebook
© 2014-2024 Fractyl Health, Inc. All Rights Reserved.
  • Contact
  • Privacy & Cookie Policy
  • Terms of Use
  • Intellectual Property
  • Transparency in Coverage
logo
  • Our Focus
    • Obesity
    • Type 2 Diabetes
  • Our Platforms
    • Revita
    • Rejuva
  • Our Science
    • Clinical Studies
    • Presentations & Publications
  • Our Company
    • Culture
    • Our Team
    • Careers
  • Our News
    • Media Kit
  • Investors